Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer
NCT03781323Phase 2Active, not recruiting
- Sponsor
- University of Rochester
- Start
- May 2019
- Primary completion
- Jun 2022
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid and oxaliplatin in rectal cancer, sponsored by University of Rochester. Primary endpoint: Complete Clinical Response at 1 year. Started May 2019; status: active, not recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03781323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781323.